Ashkan Shoamanesh: OCEANIC-STROKE Focus on Stroke Subtypes and Response to Asundexian at ISC26
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn:
”It was a pleasure to discuss the results of our secondary analyses of the OCEANIC-STROKE trial focused on qualifying ischemic stroke subtype and response to asundexian with Video Journal of Neurology (VJNeurology) at ISC26.
Our results demonstrate consistency in the treatment effect of asundexian irrespective of underlying etiology, including robust reductions in ischemic stroke in patients with qualifying stroke due to small vessel occlusive disease (HR 0.61, 95%CI 0.46-0.81) and embolic stroke of undetermined source (HR 0.53, 95%CI 0.37-0.78), without excess in major bleeding or intracranial hemorrhage!
Eagerly awaiting approval of asundexian for the betterment of stroke prevention in our patients with non-cardioembolic ischemic stroke or high-risk TIA.”
Stay updated with Hemostasis Today.
-
May 24, 2026, 13:10Thomas Pincez: Emerging Challenges in Sickle Cell Disease Gene Therapy and Cancer Risk
-
May 24, 2026, 12:04Kalpana Gupta Shekhawat: Ferritin Is More Than an Iron Marker
-
May 24, 2026, 11:50Peter Zdziarski: Making Rare Disease Research More Human
-
May 24, 2026, 11:39Bram Berkelmans: Donating with a View
-
May 24, 2026, 11:28Ratiporn Chinthammit: A Meaningful Exchange in aHUS and PNH Education
-
May 24, 2026, 11:17Mary Ann Sromoski: Transfusion Medicine and Patient Blood Management in Practice
-
May 24, 2026, 07:45Thierry Burnouf: Advances in Platelet Membrane-Coated Nanoparticles for Targeted Therapeutics and Regenerative Medicine
-
May 24, 2026, 07:39Shamala Thilarajah: Our Team Receives the NMRC Transition Award for NEUROACT-Stroke
-
May 24, 2026, 05:48Yazan Abou-Ismail: Contributing to the Future of von Willebrand Disease Management